Category: Paxlovid
Research: 14.6% Paxlovid contraindication rate for hospitalized patients with Covid-19
“We examined the prevalence of contraindications to nirmatrelvir-ritonavir in patients hospitalized with COVID-19. More...
Research: Paxlovid of no benefit to the under-65’s
“Among patients 65 years of age or older, the rates of hospitalization and death due to Covid-19 were significantly lower among those who received nirmatrelvir than among those who did not. More...
Joe Biden still testing positive for Covid after two weeks
US President Joe Biden is testing positive for Covid-19 two weeks after his initial infection according to his physician. More...
Joe Biden Paxlovid rebound
US President Joe Biden has tested positive for Covid-19 again – only days after testing negative. More...
US President Joe Biden has Covid-19 *1 update*
Biden, 79, is experiencing fatigue, a runny nose and a dry cough after testing positive. More...
Science Mag: SARS-CoV-2 already finding ways to evade Paxlovid
New lab studies shows that SARS-CoV-2 can mutate in ways that make it less susceptible to Paxlovid. More...
Anthony Fauci Paxlovid rebound
Anthony Fauci has been talking about his recent Covid infection, and seeing the infection rebound after a course of Paxlovid. More...
Pfizer: Paxlovid not effective in reducing symptoms in standard risk patients
Pfizer: “An updated analysis from 1,153 patients showed a non-significant 51% relative risk reduction”. More...
FDA on Paxlovid rebound: “there is no evidence of benefit at this time for a longer course of treatment”
The US FDA have issued a thinly veiled rebuke to Pfizer CEO Albert Bourla, after his recent comments to Bloomberg News about Covid-19 infections rebounding after treatment with Paxlovid. More...
Paxlovid: Virologic characterization of nirmatrelvir-ritonavir rebound
“Symptomatic relapse after nirmatrelvir-ritonavir therapy for early stage COVID-19 infection is associated with high viral load.”… More...